Patient Portal

Welcome to University Medicine

The Unique Role UM Plays in the Community

UM's ability to integrate the three missions of patient care, teaching and research into "a greater good" is what gives UM meaning and purpose and sets it apart from all other internal medicine practices in the state of Rhode Island. It is by embracing all three missions that we provide a unique service to our patients, our colleagues and to the worldwide community.

Learn More about Our Goals

UM's Dr. Sikov Presents Principal Results from CALGB 40603 Study

William M Sikov, MD, FACP, Associate Professor of Medicine at the Warren Alpert Medical School of Brown University and a member of the division of medical oncology and hematology in the Lifespan Comprehensive Cancer Centers and in University Medicine presented the principal results from the CALGB 40603 study Friday morning 12/13/2013 to more than 6000 attendees at the 2013 San Antonio Breast Cancer symposium. CALGB 40603 tested the addition of two agents - the chemotherapy drug carboplatin and the angiogenesis targeted monoclonal antibody bevacizumab - to standard preoperative chemotherapy in patients with an aggressive type of breast cancer called triple negative breast cancer. In a study involving 443 patients enrolled at cancer centers across the US, Dr. Sikov reported that the researchers found that the addition of either of the agents significantly increased the rate of pathologic complete responses - that is, eradication of the cancer from the breast so that at surgery all that was found was dead cancer cells and scar tissue - from 44% without carboplatin to 60% with, and from 48% without bevacizumab to 59% with. Addition of these agents to standard chemotherapy did increase the incidence of certain side effects - the side effect profile for carboplatin was less concerning than that for bevacizumab. Based on risk:benefit ratio, Dr. Sikov suggested that the addition of carboplatin could now be considered a standard approach to preoperative treatment in triple negative breast cancer, and that this regimen could form the basis for future trials.

UM's Dr. Caliendo Featured in JAMA Article

Univeristy Medicine's Dr. Caliendo was recently featured in an article in The Journal of the American Medical Association:

'ISDA: Better, Faster Diagnostics for Infectious Diseases Needed to Curb Overtreatment, Antibiotic Resistance'

The full text of the article can be found by clicking here.

Aquidneck Medical Associates to Merge with University Medicine Foundation

Medical Group Expands Care for Rhode Island Residents

Providence, Rhode Island, October 29, 2013 - Aquidneck Medical Associates and University Medicine Foundation today announced that their two physician groups will merge operations effective January 1, 2014. The new medical group will include 185 physicians and 200 staff who will serve more than 100,000 patients throughout most of Rhode Island. Both groups are leaders in health care reform.

Keivan Ettefagh, M.D., president of Aquidneck Medical Associates, says, "We expect that in the near future this merger to bring high quality specialty care closer to the residents of Newport and Portsmouth. It will allow us to expand on our 50-year tradition of great service, and soon patients will no longer have to cross two bridges and drive 30 miles to reach many specialists."

University Medicine has 15 locations throughout the state that offer primary care and 10 different medical specialties. University Medicine is an independent group which is affiliated with Brown University and Lifespan Health System. Lou Rice, M.D., president of University Medicine Foundation, says, "The combined operations will allow us to expand services to more patients, participate in new programs with insurers, enhance our technology and improve administrative services."

Aquidneck Medical Associates is comprised of 11 primary care physicians and 38 support staff. The group has been a leader in Rhode Island in patient centered care and the development of electronic patient medical records. Dr. Ettefagh noted, "A significant factor in our decision to join University Medicine is that our patients will see little if any change and our physicians and staff will be able to continue to provide personalized care for our patients. We will continue to provide care to our patients as Aquidenck Medical Associates Affiliated with University Medicine."

Joining University Medicine will enable Aquidneck to offer innovative clinical care such as their patient-centered medical homes (PCMHs); and will enhance its ability to participate in new healthcare models under the Affordable Care Act, such as accountable care organizations (ACOs).

University Medicine also has made it a priority to add more primary care physicians, which is critical given the current and projected shortage of access to primary care providers. Dr. Rice said, "The opportunity to affiliate with a high quality group like Aquidneck comes at the right time. We'll be better able to participate in new models of care that will give patients better service and access to care while keeping healthcare costs under control."

University Medicine is also in discussions with other physician groups in Rhode Island. Dr. Rice commented, "Our flexible approach makes us attractive to medical groups who want the administrative and support services we can provide, but who also want to maintain some autonomy in their operations, staffing, and clinical care delivery."

© Copyright, University Medicine

ADP Employee Portal

University Medicine
17 Virginia Avenue
Providence, RI 02905-4406